Therefore, LKB1 is an important regulator of AMPK in energy-stressed T cells [122], so the therapeutic effect of metformin-mediated AMPK may not be ideal in LKB1-deficient tumor patients. This evidence concerns the gene PRKAA1 and neoplasm.